Antibody for treating ulcerative colitis and restoring intestinal barrier function and application thereof

By designing a nano-antibody VHH3 targeting JAK1, the side effects and penetration problems of existing treatments were solved, efficient intestinal mucosal barrier repair and anti-inflammatory effects were achieved, the levels of inflammatory factors in UC mice were significantly reduced, and intestinal function was restored.

CN120699157AActive Publication Date: 2025-09-26ANKANG CENT HOSPITAL
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202510977216.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-16
Publication Date
2025-09-26
Estimated Expiration
2045-07-16

AI Technical Summary

Technical Problem

Existing JAK inhibitors cause serious systemic side effects. Traditional monoclonal antibodies have large molecular weight and poor penetrability, and have limited effects on intestinal mucosal barrier repair. There is a lack of high-affinity nanoantibodies targeting specific domains of JAK1.

Method used

A nano-antibody VHH3 targeting JAK1 was designed, which covers the key catalytic and regulatory regions of JAK1 through the enhanced antigen epitope JK1. It has high binding specificity, small molecular weight and high purity, and can accurately block JAK1 signals and promote intestinal mucosal barrier repair.

Benefits of technology

It significantly reduces serum TNF-α and IL-6 levels in UC mice, restores intestinal mucosal barrier function, improves clinical indicators, reduces disease activity index, enhances intestinal tissue permeability, and has low immunogenicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120699157A_ABST
    Figure CN120699157A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, and particularly discloses an antibody for treating ulcerative colitis and restoring intestinal barrier function and application thereof. The antibody is a VHH3 nano antibody targeting Janus kinase 1 (JAK1), and the amino acid sequence of the antibody is as shown in SEQ ID NO: 4. The antibody is specifically combined with a JAK1 antigen epitope (SEQ ID NO: 3), so that the expression of proinflammatory factors TNF-alpha and IL-6 can be remarkably inhibited, the protein distribution of colon epithelium Claudin-1 is promoted, and the intestinal barrier function is recovered. Animal experiments show that by intraperitoneal injection of 0.2-1.8 mg / kg of VHH3, the disease activity index (DAI) can be effectively reduced, and the curative effect is dose-dependent. Compared with the prior art, the affinity of the antibody reaches 1.23 nM, and the antibody has the advantages of small molecular weight, strong penetrability, low immunogenicity and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a nanobody (VHH3) targeting Janus kinase 1 (JAK1) and its application in treating ulcerative colitis and restoring intestinal barrier function, especially to the screening method, binding characteristics and in vivo anti-inflammatory mechanism of the antibody. Background Art

[0002] Ulcerative colitis (UC) is an autoimmune disease characterized by chronic inflammation of the colonic mucosa. Clinical manifestations include recurrent abdominal pain, bloody and purulent stools, diarrhea, and intestinal barrier damage with or without other systemic symptoms and extraintestinal manifestations. Existing biological agents (such as anti-TNF-α monoclonal antibodies, represented by infliximab and adalimumab) are only effective in 40-60% of patients, and long-term use is prone to the risk of infection, lymphoma, etc. (Danese et al., Gut 2020). Traditional small molecule drugs (such as 5-aminosalicylic acid, represented by mesalazine) have limited efficacy in treating moderate to severe UC, and there is an urgent need to develop new, highly effective and low-toxic targeted therapies.

[0003] Janus kinase 1 (JAK1) is a core protein mediating inflammatory signaling in ulcerative colitis (UC). Its abnormal activation can drive the release of pro-inflammatory cytokines such as IL-6 and TNF-α (Shea et al., Annu Rev Med 2015). Although JAK inhibitors (represented by tofacitinib and upadacitinib) have been approved for the treatment of UC, their broad-spectrum inhibition of JAK1 / JAK2 / JAK3 can lead to systemic side effects such as anemia, infection, and herpes zoster (Sandborn et al., NEJM 2017). Therefore, the development of inhibitors that specifically target JAK1 while avoiding off-target effects is key to breaking through the current treatment bottleneck.

[0004] Nanobodies (VHHs), derived from the variable region of heavy-chain antibodies from camels, possess properties such as small molecular weight (approximately 15 kDa), strong penetrability, and low immunogenicity (Hamers-Castermane et al., Nature 1993). However, existing nanobodies are primarily focused on tumors or infections, and there are no high-affinity nanobodies targeting JAK1 for UC treatment. In particular, the development of nanobodies targeting specific JAK1 domains still faces technical challenges such as complex epitope design and insufficient in vivo functional validation. Summary of the Invention

[0005] The present invention aims to address three major deficiencies in the treatment of ulcerative colitis (UC): 1. Existing JAK inhibitors (such as tofacitinib and upadacitinib) cause serious systemic side effects due to their broad-spectrum inhibition of the JAK family; 2. Traditional monoclonal antibodies (such as anti-TNF-α monoclonal antibodies, represented by infliximab and adalimumab) have large molecular weight and poor penetrance, and have limited effect on intestinal mucosal barrier repair; 3. There is a lack of high-affinity nanoantibodies targeting specific domains of JAK1.

[0006] The present invention provides for the first time a nanobody for treating ulcerative colitis and restoring intestinal barrier function. The nanobody is a VHH3 antibody, and the amino acid sequences of its complementary determining regions CDR1-3 are as shown in SEQ ID NOs: 6, 8, and 10, respectively.

[0007] In certain embodiments, the amino acid sequence of the Nanobody is shown in SEQ ID NO:4.

[0008] The present invention also designs an enhanced antigen epitope JK1 (SEQ ID NO: 3) based on the characteristics of the JAK1 target: the structural composition of the antigen epitope: the JAK1 functional domain FERM_C_JAK1 (SEQ ID NO: 1) and PTK_Jak1_rpt1 (SEQ ID NO: 2) are connected in series through a flexible linker (GGGGS); this epitope covers the key catalytic region (583-846aa) and regulatory region (282-426aa) of JAK1, significantly improving the specificity of antibody screening.

[0009] The present invention also provides a pharmaceutical composition comprising the nanobody and a pharmaceutically acceptable carrier.

[0010] Finally, the present invention provides an application, which is the use of the nanobody or its pharmaceutical composition in the preparation of a drug for treating ulcerative colitis and restoring intestinal barrier function.

[0011] Compared with the prior art, the present invention has at least the following beneficial effects:

[0012] The present invention provides the core characteristics of VHH3 nanobody for the first time, and its molecular characteristics are: molecular weight 12.03kDa, purity 99.3% ( Figure 4), can be efficiently expressed in prokaryotes; the affinity Kd value for JK1 antigen reaches 1.23nM; VHH3 treats UC by precisely blocking JAK1 signaling: significantly reducing the levels of TNF-α and IL-6 in the serum of UC mice; 0.2-1.8mg / kg intraperitoneal injection, the anti-inflammatory effect increases with the dose; the core evidence of VHH3 repairing the intestinal mucosal barrier lies in upregulating tight junction proteins, that is, promoting the expression and distribution of colon Claudin-1, and the proportion of positive areas in the high-dose group (1.8mg / kg) returned to more than 90% of the normal level; at the same time, it improves clinical indicators, that is, achieving a dose-dependent reduction in the disease activity index (DAI); the small molecule characteristics of VHH3 nanoantibodies enhance intestinal tissue penetration, and its immunogenicity is lower than that of traditional monoclonal antibodies. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 Schematic diagram of the structure of the JK1 antigen fragment.

[0014] Figure 2 SDS-PAGE identification of JK1 antigen fragments.

[0015] Figure 3 Positive clones were detected by ELISA.

[0016] Figure 4 SDS-PAGE characterization of VHH3 nanobody.

[0017] Figure 5 Affinity detection of VHH3 nanobody binding to antigen protein.

[0018] Figure 6 Disease activity index (DAI) detection in ulcerative colitis model mice.

[0019] Figure 7 The expression levels of TNF-α and IL-6 in mouse serum were detected by enzyme-linked immunosorbent assay (ELISA).

[0020] Figure 8 The expression distribution of Claudin-1 in the colon of ulcerative colitis model mice. DETAILED DESCRIPTION

[0021] In order to make the technical problems, technical solutions and advantages to be solved by the present invention clearer, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0022] Example 1. Preparation of Janus Kinase 1 (JAK1) Antigen

[0023] The epitope sequence was based on the domain of Janus kinase 1 (aprotein tyrosine kinase) [Homo sapiens], GenBank: AAI32730.1, as recorded by NCBI:

[0024] FERM_C_JAK1(282..426):

[0025] GAEIFETSMLLISSENEMNWFHSNDGGNVLYYEVMVTGNLGIQWRHKPNV

[0026] VSVEKEKNKLKRKKLENKHKKDEEKNKIREEWNNFSYFPEITHIVIKESVVS INKQDNKKMELKLSSHEEALSFVSLVDGYFRLTADAHHYLCTD(SEQ ID NO:1);

[0027] PTK_Jak1_rpt1(583..846):

[0028] LVQGEHLGRGTRTHIYSGTLMDYKDDEGTSEEKKIKVILKVLDPSHRDISLA

[0029] FFEAASMMRQVSHKHIVYLYGVCVRDVENIMVEEFVEGGPLDLFMHRKSD

[0030] VLTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNLLAREGIDSECGPFI

[0031] KLSDPGIPITVLSRQECIERIPWIAPECVEDSKNLSVAADKWSFGTTLWEICY

[0032] NGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRCMNYDPNQRPFFRAIMRDIN(SEQ ID NO:2);

[0033] The enhanced JAK1-C antigen epitope fragment was prepared by concatenating FERM_C_JAK1 and PTK_Jak1_rpt1 with linker (GGGGS):

[0034] GAEIFETSMLLISSENEMNWFHSNDGGNVLYYEVMVTGNLGIQWRHKPNVVSVEKEKNKLKRKKLENKHKKDEEKNKIREEWNNFSYFPEITHIVIKESVVSINKQDNKKMELKLSSHEEALSFVSLVDGYFRLTADAHHYLCTDGGGGSGGGGSGGGGSGGGGSLVQGEHLGRGTRTHIYSGTLMDYKDDEGTSEEKKIKVILKVLDPSHRDISL AFFEAASMMRQVSHKHIVYLYGVCVRDVENIMVEEFVEGGPLDLFMHRKSDVLTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNLLLAREGIDSECGPFIKLSDPG IPITVLSRQECIERIPWIAPECVEDSKNLSVAADKWSFGTLWEICYNGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRCMNYDPNQRPFFRAIMRDIN(SEQ ID NO:3);

[0035] NdeⅠ and XbaⅠ were introduced into the beginning and end of the fragment, respectively, and the fragment was named JK1( Figure 1 ), synthesized by Nanjing GenScript Biotechnology Co., Ltd.

[0036] The synthesized JK1 protein antigen epitope fragment was cloned into the expression vector pCZN1, and the ligation product was transformed into Arctic-Express BL21 (DE3) competent cells and coated on LB (containing Amp) plates for culture. After that, a single clone was picked and transferred to LB liquid culture medium, cultured in a constant temperature shaker at 37°C and 120r / min until the D600 value was 0.6-0.8, and then IPTG was used for further induction. The cells were centrifuged at 5000r / min for 10min, the supernatant was discarded, and the cells were collected. After ultrasonic lysis and disruption, the cells were centrifuged at 8000r / min for 10min, and the supernatant containing the JK1 target protein was collected. The protein was purified using the His tag protein purification kit (Ni-NTA) (Sangon Biotech (Shanghai) Co., Ltd.), and finally protein expression was identified by SDS-PAGE. Figure 2 .

[0037] Figure 2 The results showed that the molecular weight of the JK1 antigen fragment was 48.50 kDa and the purity was 99.4%.

[0038] Example 2. Screening, expression and identification of anti-Janus kinase 1 (JAK1) nanobodies

[0039] After obtaining sufficient antigen, camels were immunized. 1 mg of JK1 antigen protein was mixed with Freund's adjuvant in a 1:1 ratio. Complete Freund's adjuvant was used for the first immunization, followed by incomplete Freund's adjuvant for the next five immunizations, for a total of six immunizations, with a one-week interval between each. One week before immunization and one week after the last immunization, 100 mL of peripheral blood was collected, and the upper serum was collected for antibody titer testing. Peripheral blood lymphocytes were isolated, and total RNA was extracted using an RNA extraction kit. RNA was then reverse-transcribed into cDNA using a reverse transcription kit. Nested PCR was used to obtain the VHH nucleic acid sequence of the Nbs. The VHH nucleic acid sequence of the Nbs and the vector pMECS were digested with the restriction endonucleases PstI and NotI, respectively, ligated with T4 DNA ligase, and electroporated into Escherichia coli TG1 to complete the JK1 phage library construction.

[0040] The purified JK1 protein (diluted to 10 mg / L) was coated onto a 96-well plate, with 100 μL added to each well. A negative control well (PBS-coated) was also set up and blocked overnight at 4°C. The coating solution was discarded, the plates were washed three times with 0.05% PBST, 200 μL of 5% skim milk was added, and the plates were incubated at 37°C for 2 h. The plates were washed three times with 0.05% PBST, and 100 μL of the JK1 phage library prepared above (adjusted to a concentration of 1.2 × 10 9 PFU / mL) and incubate at 37°C for 2 h. Discard the phage sample, wash three times with 0.05% PBST, add 100 μL of 0.1 mol / L triethylamine solution to each well, let it stand at room temperature for 10 min, and then add the same volume of 1 mol / L Tris-HCl (pH 7.4) to neutralize it to obtain the first round of eluate. The eluted recombinant phage is then titered in the first round, which is the first round of panning. Repeat the above steps for a total of three rounds of panning to effectively enrich the positive phage.

[0041] The TG1 bacteria were infected with phages from the third round of panning, and the bacterial solution was spread on a 2YTAG solid culture plate. 98 single clones were randomly selected and transferred to the culture medium. After shaking and culturing at 37°C, they were transferred to a 96-well deep-well plate. KM13 helper phage was added and cultured overnight to release the phage into the supernatant. The supernatant was aspirated and added to ELISA plates pre-coated with JK1 antigen. After reacting overnight, an anti-M13 phage antibody conjugated to HRP was added as a secondary antibody. The positive clones were detected by ELISA and the D450 value was measured. The D450 value of the sample well was set as P, and the D450 value of the negative control well was set as N. The clones with P / N ≥ 3 were considered positive, and the strain with the largest ratio was selected for sequencing. Figure 3 .

[0042] Figure 3The results showed that clones with P / N ≥ 3 were judged as positive, and a total of 4 positive clones were found that could specifically bind to the JK1 antigen. Among them, the OD value of VHH3 was significantly higher than that of other positive clones. Therefore, VHH3 was subsequently sequenced, expressed, and purified.

[0043] The TG1 strain corresponding to the screened VHH3-positive clone was revived and cultured, and the phage plasmid DNA it carried was extracted; bidirectional sequencing was performed by the Sanger dideoxy chain termination method using universal sequencing primers on both sides of the phagemid vector; the obtained sequencing peaks were spliced, translated, and sequenced to confirm the integrity of the open reading frame, especially the sequence of the CDR1-3 region, and finally the accurate gene sequence and deduced amino acid sequence of the VHH3 nanobody were obtained, see Table 1.

[0044] Table 1. Sequencing results of VHH3 nanobodies

[0045]

[0046] The sequenced VHH3 was inserted into the pCZN1 vector with a HIS tag to construct the pCZN1-VHH3 recombinant plasmid and transformed into Arctic-Express competent cells for expression. The cells were cultured at 37°C overnight. Positive clones were picked and inoculated into LB liquid medium. The cells were cultured at 37°C and 2000 rpm overnight. VHH3 was further purified by Ni column affinity chromatography. The size and purity of the nanobody were identified by SDS-PAGE. Figure 4 .

[0047] Figure 4 The results showed that the size of the HIS-tagged VHH3 nanobody was 12.03 kDa, consistent with expectations, and the purity was 99.3%.

[0048] JK1 antigen was diluted to 1 μg / mL using PBS buffer as the antigen diluent, and 100 μL / well was added to a high-absorption 96-well plate and incubated at 4°C overnight. The plate was washed five times with 200 μL / well of PBST buffer, patted dry, and immediately added with 300 μL of blocking solution and incubated at room temperature for 1 hour. The plate was washed three times with 300 μL / well of PBST buffer, patted dry, and then serially diluted VHH3 nanobody starting at 100 μg / mL was added at 100 μL / well and incubated at room temperature for 90 minutes. The plate was washed five times with 200 μL / well of PBST buffer, patted dry, and then HRP-conjugated anti-His tag secondary antibody (1:2500 dilution) was added to the wells and incubated at room temperature for 60 minutes. The plate was washed again five times with 200 μL / well of PBST buffer and patted dry. Add 100 μL / well of TMB solution to the reaction plate and observe whether there is color development. After the reaction is completed, add 60 μL / well of 2M sulfuric acid to terminate the reaction. Gently tap the edge of the plate until the color in the well is uniform. Then read the plate immediately and measure the OD450 value. Figure 5 .

[0049] Figure 5 The results showed that the affinity of the VHH3 nanobody for binding to the antigen protein was 1.23nM, providing a basis for the subsequent study of candidate antibodies in experimental animals.

[0050] Example 3: Application of VHH3 Nanobodies in Treating Ulcerative Colitis Mouse Model

[0051] Forty SPF Balb / c mice (20 g to 25 g, 8 weeks old) were randomly divided into five groups (n=8): blank control group, model group (DSS), VHH3 low-dose group (0.2 mg / kg), VHH3 medium-dose group (0.6 mg / kg), and VHH3 high-dose group (1.8 mg / kg). Except for the blank control group, the mice in the other groups were given 3% DSS in drinking water for 7 consecutive days to induce acute ulcerative colitis. Starting from the day of DSS induction, the mice in each VHH3-treated group were intraperitoneally injected with the corresponding dose of VHH3 nanoantibody (dissolved in PBS, injection volume 10 μL / g body weight) every day, and the model group was injected with the same volume of PBS. Body weight, stool characteristics and blood in stool were recorded daily, and the disease activity index (DAI) was calculated, where DAI score = (body weight change score + stool morphology score + blood in stool score) / 3, see Figure 6 .

[0052] Table 2 Disease Activity Index

[0053] Evaluation indicators Scoring Rules Score 1. Weight changes Weight gain or no change 0 1-5% weight loss (relative to initial weight) 1 6-10% weight loss 2 11-15% weight loss 3 Weight loss > 15% 4 2. Stool characteristics Normally formed particles 0 Soft stools (slightly sticky but retains its shape) 1 Loose stools (semi-solid, slightly sticky to the anus) 2 Loose stools (liquid, no solids, tends to stick to the anus) 3 Watery stools (completely liquid and flows out spontaneously) 4 3. Degree of blood in stool No blood in stool (normal stool color, negative occult blood test) 0 Occult blood positive (not visible to the naked eye, requires confirmation by benzidine method / test paper) 1 Slightly bloody stools (a small amount of blood or light pink on the stool surface) 2 Obvious blood in stool (stool is red or dark red) 3 Severe bloody stools / rectal bleeding (spotting or clots from the anus) 4

[0054] Figure 6The results showed that all mice that drank DSS had elevated DAI scores, demonstrating the successful establishment of a UC mouse model. Compared to the model group, DAI scores were significantly reduced in all VHH3 dose groups (P < 0.05), indicating that elevated DAI scores in UC mice were alleviated, and this improvement became more pronounced with increasing VHH3 concentration.

[0055] Enzyme-linked immunosorbent assay (ELISA) kits (NeoBioscience, Beijing) were used to detect the expression levels of TNF-α and IL-6 in mouse serum. Figure 7 .

[0056] Figure 7 The results showed that the levels of proinflammatory factors TNF-α and IL-6 in the serum of mice in the model group were significantly higher than those in the blank control group (P < 0.05), indicating that the UC mouse model was successfully constructed, that is, DSS can cause oxidative stress response in the body by activating TNF-α and IL-6 proinflammatory factors; however, after intervention with VHH3 nanoantibodies, the levels of TNF-α and IL-6 were significantly lower than those in the model group (P < 0.01); this indicates that VHH3 nanoantibodies can inhibit the overexpression of proinflammatory factors TNF-α and IL-6, reduce inflammatory responses, repair intestinal barrier damage and achieve the purpose of treating ulcerative colitis.

[0057] The colon tissues of the mice in the above groups were fixed with 4% paraformaldehyde, embedded in paraffin, and then 4 μm thick sections were prepared. The sections were then dewaxed and hydrated, antigen heat retrieval (pH 6.0 sodium citrate buffer), and endogenous peroxidase was blocked with 3% H2O2. Rabbit anti-Claudin-1 primary antibody (1:200 dilution) was added to the sections and incubated overnight at 4°C. After rinsing with PBS, the sections were incubated with HRP-labeled goat anti-rabbit secondary antibody (1:500) at room temperature for 1 hour, stained with DAB colorimetric reagent, counterstained with hematoxylin for nuclei, and mounted with neutral gum. Five non-overlapping fields (200×) were randomly selected using Image-Pro Plus 6.0 software to determine the proportion of the brown-positive area. The data were expressed as the percentage of the positive area (%). One-way analysis of variance (ANOVA) was used for comparison between groups. Figure 8 .

[0058] Figure 8The results showed that compared with the blank control group, the area of ​​Claudin-1 protein positive expression in the colon tissue of the model group mice was significantly reduced (P < 0.05). In the low-, medium-, and high-dose VHH3 groups, the area of ​​Claudin-1 protein positive area was significantly increased compared with the model group (P < 0.05), especially in the high-dose VHH3 group, where the increase in positive area was more significant. This suggests that after intervention with VHH3 nanoantibodies, the expression and distribution of Claudin-1 protein can be promoted, bringing it close to that of the blank control group, achieving the effect of treating ulcerative colitis by maintaining the intestinal epithelial barrier function.

[0059] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. A nanobody for treating ulcerative colitis and restoring intestinal barrier function, characterized in that: The nanobody is a VHH3 antibody, and the amino acid sequences of its complementary determining regions CDR1-3 are shown in SEQ ID NOs: 6, 8, and 10, respectively.

2. The Nanobody according to claim 1, characterized in that The nanobody specifically binds to a JAK1 antigen epitope having an amino acid sequence as shown in SEQ ID NO:

3.

3. The Nanobody according to any one of claims 1-2, characterized in that The amino acid sequence of the Nanobody is shown in SEQ ID NO:

4.

4. The Nanobody according to any one of claims 1 to 3, characterized in that The affinity of the nanobody to the JAK1 antigen is 1.23 nM and the molecular weight is 12.03 kDa.

5. A pharmaceutical composition comprising the Nanobody according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

6. Use of the Nanobody according to any one of claims 1 to 4 or the pharmaceutical composition according to claim 5 in the preparation of a medicament for treating ulcerative colitis.

Citation Information

Patent Citations

  • Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices

    CN110072519A

  • Methods of treating crohn's disease and ulcerative colitis

    CN110392572A

  • Compound capable of inhibiting and degrading activity of Janus kinase (JAK1 or JAK2)

    CN110407915A

  • JAK1 pathway inhibitors for the treatment of gastrointestinal disease

    CN113692278A

  • Application of JAK1 protein ubiquitination site in preparation of interferon tolerant cells

    CN116064461A